Jeremy Marcus, MD
Nephrology · Washington, DCNPI 1528175114
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,250 of the $1,391 with a category attached, or 89.9%. It is spread thinly across 14 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $499, more than ten times the $20 reported in 2020.
Across 58 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$331
- Amgen$175
- Novo Nordisk$162
- Vifor Pharma, Inc.$142
- Novartis$137
- AstraZeneca$81
- plus $363 from 8 others
What the payments were for
- Food & beverage$1,25090%
- Education$14110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 15 | $331 |
| Amgen | 7 | $175 |
| Novo Nordisk | 3 | $162 |
| Vifor Pharma, Inc. | 6 | $142 |
| Novartis | 6 | $137 |
| AstraZeneca(2 entities) | 3 | $81 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Lilly USA, LLC | 3 | $70 |
| Akebia Therapeutics Inc | 2 | $51 |
| Bayer | 2 | $42 |
| Travere Therapeutics, Inc. | 4 | $41 |
| Boehringer Ingelheim | 1 | $35 |
| Calliditas Therapeutics US Inc. | 1 | $22 |
| GSK | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$116
How this compares
$1,391 in reported general payments places this provider in the 65th percentile of 62 nephrology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 108 | $133,565 |
| JardianceEmpagliflozin | 88 | $133,310 |
| AlyqTadalafil | 13 | $44,545 |
| LokelmaSodium Zirconium Cyclosilicate | 34 | $33,571 |
| VeltassaPatiromer Calcium Sorbitex | 28 | $31,476 |
| OzempicSemaglutide | 11 | $14,884 |
| Sevelamer Carbonate | 39 | $12,901 |
| ProcritEpoetin Alfa | 11 | $7,921 |
| GemtesaVibegron | 12 | $6,727 |
| Potassium Citrate ErPotassium Citrate | 28 | $3,898 |
| Tacrolimus | 20 | $2,312 |
| Chlorthalidone | 79 | $2,142 |
| Nifedipine ErNifedipine | 45 | $1,842 |
| Calcium Acetate | 21 | $1,588 |
| Irbesartan | 44 | $1,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $81 | $167,137142 claims |
| Boehringer IngelheimJardiance | $35 | $133,31088 claims |
| Novo NordiskOzempic | $162 | $14,88411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 62 nephrology providers in District of Columbia.
Other nephrology in Washington
- Ashte CollinsWashington$1M
- Bruce LeslieWashington$217K
- Janani RangaswamiWashington$152K
- Robert RubinWashington$119K
- Ehsan Nobakht HaghighiWashington$50K
- Christopher WilcoxWashington$41K
- Michael LipkowitzWashington$21K
- Dominic RajWashington$19K
- Cosette JamiesonWashington$13K
- Elwin BustosWashington$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.